Terms ending in 2029
Every in-force patent on Amgen Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,288,339 | GLP-1 Compounds In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,946,152 | Method of Treating Parkinson's Disease in Humans by Convection-Enhanced Infusion of Glial Cell-Line Derived Neurotrophic Factor to the Putamen In force · Medium confidence | Amgen Inc. | In force | Medium confidence | |
| US 9,175,078 | Ferroportin Antibodies and Methods of Use In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 9,688,759 | Ferroportin Antibodies and Methods of Use In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,221,749 | Antibodies Directed to ANGIOPOIETIN-1 and ANGIOPOIETIN-2 and Uses Thereof In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 10,336,820 | Antibodies Directed to ANGIOPOIETIN-1 and ANGIOPOIETIN-2 and Uses Thereof In force · High confidence | Amgen Inc. | In force | High confidence | |
| US D723,157 | Drug Delivery Pump In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 8,093,299 | Methods of Treating Bowel Disorders In force · High confidence | Yale University | In force | High confidence | |
| US 7,947,809 | Compositions and Methods Relating to Glucagon Receptor Antibodies In force · High confidence | Amgen Inc. | In force | High confidence | |
| US 7,960,567 | Compounds and Methods Useful for Treating Asthma and Allergic Inflammation In force · High confidence | Amgen Inc. | In force | High confidence | |
| 46 more term ends in 2029 · Pro | |||||
10 of 56 patents shown. Soonest term end first, then patent number.
Pro members see all 56.
52 of these are in force and held by Amgen Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.